SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter
Summit Therapeutics (SMMT) saw price target reductions from Barclays ($18) and Citi ($42) after the FDA issued a complete response letter for its lung cancer treatment, ivonescimab. Barclays noted potential implications for the lung cancer program, while Citi cited the CRL as the reason for its reduction. Jefferies maintained a 'Buy' rating with a $30 target, stating the setback was anticipated. SMMT shares fell 11% following the news.
How this was made

The 30-second read
Why it matters
Analyst target cuts reflect belief that the regulatory hurdle lowers near‑term valuation, but continued development in other indications may preserve long‑term upside.
Market read
The FDA CRL and subsequent analyst target reductions create immediate bearish pressure on SMMT, with potential spill‑over to similar biotech stocks.
What to watch
Potential for the drug to succeed in first‑line settings or colorectal cancer could mitigate the impact of this CRL.
Background
Summit Therapeutics is developing ivonescimab for NSCLC; the FDA CRL cites insufficient overall‑survival benefit despite progression‑free survival improvement.
Ticker impact
FDA issued a complete response letter for Summit's ivonescimab lung‑cancer application, prompting analysts to cut price targets and the stock fell 11%.
likely pressure as the market prices in the FDA CRL and lowered analyst targets
The CRL is a material regulatory event for a biotech; analysts have already reduced targets, indicating bearish sentiment.
Market effects
Other lung‑cancer biotech peers may see heightened scrutiny on trial data.
US biotech sector could face short‑term pressure.
Limited to biotech investors; no broad market effect.
Counterpoint
If Summit can demonstrate efficacy in other indications, the stock may rebound on future data.
Key entities
- companySummit Therapeutics
Biotech firm developing ivonescimab.
- regulatorFDA
Issued the complete response letter.




